Clinical Data Wave crashes on obesity drug update; Kodiak’s reboot pays dividends BioPharma DiveWave s drug, which is meant to improve body composition, disappointed investors but was defended by analysts.Clinical DataMetabolic & GLP-1Read full story pharminent March 26, 2026 (Last updated: March 27, 2026) BioPharma Dive Wave s drug, which is meant to improve body composition, disappointed investors but was defended by analysts. Clinical DataMetabolic & GLP-1Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Maze tumbles despite positive data for kidney disease drugNext: FDA clears Denali drug in ‘clear step’ for rare disease biotechs Related Stories Clinical Data Parsortix study shows promise for ADC target detection pharminent August 3, 2026 Clinical Data Novo setback casts doubt on a new way to treat heart disease pharminent July 31, 2026 Clinical Data Altimmune rises as GLP-1/GIP drug curbs heavy drinking in mid-stage study pharminent July 28, 2026
